Table 3.

NEDA-3 for fingolimod and natalizumab in the first year of treatment for patients that began the treatment in 2013 and 2014.

n = 281		NEDA-3 in the First Year of Treatment n (%)	p
All	NEDA-3 No-NEDA	169 112
Fingolimod	NEDA-3 No-NEDA	97 (53.9) 83 (46.1)	p < 0.0001
Natalizumab	NEDA-3 No-NEDA	72 (71.3) 29 (28.7)

NEDA, no evidence of disease activity; available data from n = 281.